Cytonus Therapeutics, Inc.
Deadline ahead 2027-04-30Corporation · Delaware · Incorporated 2018-08-21
- CIK 1761468
- File 020-37486
- State DE
- Target Amount
- $50,000
- minimum to close
- Maximum Amount
- $1,000,000
- ceiling, with over-subscription
- Deadline
- 2027-04-30
- as the latest Form C set it
Connected
named in its Form C filingsThe intermediary named in this company’s Form C filings. Investments in a Regulation Crowdfunding offering can only be made through them.
Latest Reported Offering
The terms on the latest Form C
Security Details
- Type
- Preferred Stock
- Price per share
- $12.04
- Price set by
- Dividing pre-money valuation $96,030,426 (or $80,000,000 for investors in the first $100,000), which valuation was determined by management, by number of shares outstanding on fully diluted basis.
- Shares offered
- 4,153+
Offering Costs
- Cash commission
- —
- 7.9% of the offering amount upon a successful fundraise, and reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.
- Equity compensation
- —
- No
Campaign timeline
target amount · by first filed- 2026-10-27$50,000020-37486
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($50,000)
Reg D offerings
5 offeringsPrivate placements reported on Form D, separate from the crowdfunding raise: Reg CF sales are never counted in their sold amounts
| File | First filed | Latest | Sought | Sold | Investors | Exemption |
|---|---|---|---|---|---|---|
| 021-496564 | First filed2023-11-06 | Latest2023-11-06 | Sought$21.6M | Sold$11.7M | Investors19 | Exemption506(b) |
| 021-433094 | First filed2022-02-10 | Latest2022-02-10 | Sought$1M | Sold$15K | Investors1 | Exemption506(b) |
| 021-392699 | First filed2021-03-18 | Latest2021-03-18 | Sought$5M | Sold$2.5M | Investors1 | Exemption506(b) |
| 021-366053 | First filed2020-04-30 | Latest2020-04-30 | Sought$1M | Sold$100K | Investors2 | Exemption506(b) |
| 021-328862 | First filed2018-12-26 | Latest2018-12-26 | Sought$3M | Sold$70K | Investors2 | Exemption506(b) |
Company Information
- Legal Status
- Corporation
- Jurisdiction
- Delaware
- Date of Incorporation
- 2018-08-21
- Website
- https://axiombio.co
Latest Metrics
Most recent fiscal year, as the latest filing reports it
- Employees
- 3
- Total Assets
- $2,016,065
- Cash on Hand
- $581,452
- Revenues
- $1,275,587
- Net Income
- -$2,244,653
The reported figures behind Cytonus Therapeutics, Inc.
Form C prints a most-recent and a prior fiscal year side by side but never names them. The dashboard chains every filing into those years and plots them. EDGAR still has each Form C-AR; the dashboard lays every year they filed next to it.
- Reported financials chained into fiscal years — revenue, income, assets, cash — not one filing at a time
- A sparkline on each figure so the shape is visible before the numbers
- A revenue series dated to the filings that reported it
- The campaign as filed: target, ceiling, deadline, and the portal that ran it
- Follow it, and see it change on your watchlist
Part of the Crowdfunding plan — $40/mo at launch pricing ($100 list)
See plans
